

GENOMIC VALLEY BIOTECH LIMITED

[CIN : L01122HR1994PLC033029]



4 KM Stone, Berri Chhara Road, P.O. Tanda Heri, Tehsil
Bahadurgarh, District Jhajjar, HARYANA, INDIA - 124 507

genomicvalley@gmail.com

www.genomicvalley.com

+91 9811341542

Date: 20th July, 2022

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort
Mumbai-400001
Email ID: corp.relations@bseindia.com

Ref: Genomic Valley Biotech Limited (539206/ GVBL)

Sub: Submission of Outcomes of Board Meeting and Un-Audited Financial Results for the quarter and three months ended 30th June, 2022

1. Intimation and disclosure under Regulations 30 & 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for Un-Audited Financial Results and Limited Review Report for the quarter and three months ended 30.06.2022

Dear Sir/ Madam,

Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of Genomic Valley Biotech Limited ("Company") in its meeting held today approved the Un-Audited Financial Results (Standalone) for the Quarter and three months ended 30th June, 2022 of the Company as per Indian Accounting Standards (IND-AS) along with the Limited Review Report. Copy of the results along with the Limited Review Report of Statutory Auditors is attached herewith for your perusal.

The above information will also be available on the Company's Website, www.genomicvalley.com.

The meeting of the Board of Directors commenced on 11:00 A.M. and concluded at 01:00 P.M.

Please take the above on records.

Thanking you.

Yours sincerely

For Genomic Valley Biotech Limited



Yogesh Agrawal
Managing Director
DIN: 01165288
Add: G-74, Pushkar Enclave,
Paschim Vihar Delhi - 110063

GENOMIC VALLEY BIOTECH LIMITED
Regd. Off: 4 K.M. STONE, BERRI CHHARRA ROAD, P.O. TANDAHERI,
TEHSIL-BAHADURGARH, DISTT-JHAJJAR, HARYANA-124507
CIN: L01122HR1994PLC033029

Genomic Valley Biotech Limited today reported its financial performance for the quarter and three months ended
30 June 2022


Highlights of the Un-Audited Financial Results as compared to the previous year are:

Part I

In Rs.

Sr. No.	Particular	3 months ended		Corresponding 3 months ended in the previous year	
		30-Jun-22	31-Mar-22	30-Jun-21	31-Mar-22
		Un-Audited	Audited	Un-Audited	Audited
I	Revenue From Operations	10,338,000	-	169,600	705,640
II	Other Income	144,877	55,522	-	840,070
III	Total Revenue (I+II)	10,482,877	55,522	169,600	1,545,710
IV	Expenses				
	Cost of materials consumed	-	-	-	19,410
	Purchases of Stock-in-Trade	9,817,600	-	-	-
	Changes in inventories of finished goods work-in-progress and Stock-in-Trade	-	-	-	-
	Employee benefits expense	825,487	842,081	177,200	1,398,781
	Financial costs	-	-	426,203	426,203
	Depreciation and amortization expense	76,324	-499,841	470,238	840,873
	Other expenses	275,549	2,370,645	183,714	3,068,718
	Total Expenses (IV)	10,994,960	2,712,885	1,257,355	5,753,985
V	Profit / (Loss) before exceptional item and tax (III-IV)	-512,083	-2,657,363	-1,087,755	-4,208,275
VI	Exceptional Item	5,104,788	4,191,783	-	4,191,783
VII	Profit/loss before Tax (V-VI)	4,592,705	1,534,421	-1,087,755	-16,492
VIII	Tax expenses				
	(1) Current Tax	-	-	-	-
	(2) Deferred Tax	-	76,910	-	76,910
IX	Profit/ (Loss) for the period from continuing operations (VII-VIII)	4,592,705	1,457,511	-1,087,755	-93,402
X	Profit/ (Loss) from discontinued operations	-	-	-	-
XI	Tax expense of discontinued operations	-	-	-	-
XII	Profit/ (Loss) from discontinuing operations (after tax) (X-XI)	-	-	-	-
XIII	Profit/Loss for the period (IX+XII)	4,592,705	1,457,511	-1,087,755	-93,402

Handwritten signature



XIV	Other Comprehensive Income				
A	(i) Items that will not be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-
B	(i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit/ (Loss) and other Comprehensive Income for the period)	4,592,705	1,457,511	-1,087,755	-93,402
XVI	Paid up Equity Share Capital, Equity Share of ₹ 10/- each	3,054,500	3,054,500	3,054,500	3,054,500
XVII	Earning Per Equity Share (for continuing operation):				
	1) Basic	1.50	0.48	-0.36	-0.03
	2) Diluted	1.50	0.48	-0.36	-0.03
XVIII	Earning Per Equity Share (for discontinued operation):				
	1) Basic	0.00	0.00	0.00	0.00
	2) Diluted	0.00	0.00	0.00	0.00
XIX	Earning Per Equity Share (for discontinued & continuing operations):				
	1) Basic	1.50	0.48	-0.36	-0.03
	2) Diluted	1.50	0.48	-0.36	-0.03

Notes :

- The above Financial Results were reviewed by the Members of Audit Committee and approved by the Board of Directors at their respective Meeting held on 20th July, 2022. The Statutory Auditors of the company have carried out a Limited Review of the Financial Results for these financials.
- The Company has adopted Indian Accounting Standards (Ind AS) notified by Ministry of Corporate Affairs from 1st April 2017, with a transition date 1st April 2016 and accordingly these financial Result have been prepared in accordance with the companies (Indian Accounting Standard) Rules, 2015 prescribed under section 133 of the Comapnies Act, 2013 and other accounting principles generally accepted in India.
 - Figures for the prior period have been regrouped and / or rearranged wherever considered necessary as per the revised format prescribed by SEBI under SEBI (LODR) Regulations, 2015 and amended as per the Schedule III of the Companies Act, 2013.

For and on behalf of the Board of Genomic Valley Biotech Limited



Yogesh Agrawal
Yogesh Agrawal
(Managing Director)
DIN-01165288

Add: G-74 Pushkar Enclave
Paschim Vihar, New Delhi-110063

Place : Delhi
Dated : 20.07.2022

ANDROS & CO.
CHARTERED ACCOUNTANTS

901, TOWER-1, PEARL OMAXE, PLOT B-1,
NETAJI SHUBHASH PLACE, PITAMPURA
DELHI-110034
Ph-011-47060901
Email: cabhavukgarg@gmail.com

LIMITED REVIEW REPORT

To,
The Board of Directors of
Genomic Valley Biotech Limited,
4 K.M. Stone, Berri Chharra Road,
Village- Kherka Musalman, P.O. Tandaheri,
Tehsil- Bahadurgarh, District-Jhajjar, Haryana-124507.

**Subject: Limited Review Report on the Un-Audited Financial Results for the Quarter and
Three Months ended on 30th June, 2022**


We have reviewed the accompanying statement of unaudited financial results for **the Quarter and Three Months ended on 30th June, 2022** ('the statement') of Genomic Valley Biotech Limited ('the Company') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016.

This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

This Statement has been prepared by the Company's Management in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited Financial Results prepared in accordance with recognition and measurement principles laid down in the applicable Indian Accounting Standards, prescribed under Section 133 of Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.



For ANDROS & CO.
Chartered Accountants
FRN: 008976N

Bhavuk Garg

(CA Bhavuk Garg)
(Partnership Firm)
(Membership No.-502310)

Place: Delhi
Date: 20-07-2022

UDIN: 22502310-ANGTJM-1714
Peer Review: 012121